Autoantibody Profiling in Systemic Autoimmune Disease Research

Autoantibodies are the serological hallmark of systemic autoimmune rheumatic diseases — they serve as disease activity biomarkers and predictors of organ involvement. Traditional autoantibody testing relies on a tiered approach: initial screening by indirect immunofluorescence (IIF) on HEp-2 cells for ANA, followed by single-analyte confirmation assays (ELISA, FEIA, or immunoblot) for individual specificities. This workflow is labor-intensive, consumes significant sample volume, and produces semi-quantitative IIF results requiring subjective pattern interpretation. Electrochemiluminescence — via U-PLEX custom configuration — offers an alternative: quantitative, multiplexed measurement of multiple autoantibody specificities simultaneously from 25 µL of serum or plasma, with the wide dynamic range and low background characteristic of ECL detection.

Key Autoantibody Specificities

  • SLE markers (dsDNA, Sm, Ribosomal P, Chromatin, C1q): Anti-dsDNA titers correlate with disease activity, rising before renal flares. Anti-Sm is highly SLE-specific. Anti-ribosomal P is associated with neuropsychiatric SLE.
  • RA markers (RF + anti-CCP): RF is sensitive but non-specific. Anti-CCP is >95% specific for RA, predicts erosive disease. Combined measurement from 25 µL enables quantitative serological RA phenotyping.
  • Sjogren's markers (SSA/Ro52, SSA/Ro60, SSB/La): Defining serological markers of primary Sjogren's syndrome. Distinguishing anti-Ro52 from anti-Ro60 provides clinical granularity — isolated anti-Ro52 associates with myositis and ILD.
  • Scleroderma markers (Scl-70, Centromere B, RNA Pol III): Anti-Scl-70 associates with diffuse SSc and ILD. Anti-centromere B with limited SSc/CREST. Anti-RNA Pol III links to renal crisis.
  • Myositis markers (Jo-1, PL-7, PL-12, SRP, Mi-2, TIF1-γ, MDA5): Anti-Jo-1 is the most common myositis-specific autoantibody, associated with anti-synthetase syndrome.